AbbVie (GB:0QCV)
LSE:0QCV
Holding GB:0QCV?
Track your performance easily

AbbVie (0QCV) Income Statement

7 Followers

AbbVie Income Statement

Last quarter (Q3 2024), AbbVie's total revenue was $14.46B, an increase of 3.83% from the same quarter last year. In Q3, AbbVie's net income was $1.56B. See AbbVie’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 55.53B$ 54.32B$ 58.05B$ 56.20B$ 45.80B$ 33.27B
Cost of Revenue
$ 18.21B$ 20.41B$ 17.41B$ 17.45B$ 15.39B$ 7.44B
Gross Profit
$ 37.32B$ 33.90B$ 40.64B$ 38.75B$ 30.42B$ 25.83B
Operating Expense
$ 22.72B$ 20.37B$ 21.83B$ 20.80B$ 19.06B$ 12.84B
Operating Income
$ 13.82B$ 12.76B$ 18.12B$ 17.92B$ 11.36B$ 12.98B
Net Non Operating Interest Income Expense
$ -1.93B$ -1.68B$ -2.04B$ -2.38B$ -2.28B$ -1.51B
Other Income Expense
$ -5.63B$ -5.60B$ -3.29B$ 2.50B$ 5.61B$ 3.01B
Pretax Income
$ 7.20B$ 6.25B$ 13.48B$ 12.99B$ 3.40B$ 8.43B
Tax Provision
$ 2.06B$ 1.38B$ 1.63B$ 1.44B$ -1.22B$ 544.00M
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ 5.08B$ 4.82B$ 11.78B$ 11.47B$ 4.56B$ 7.88B
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 41.71B$ 40.78B$ 39.24B$ 38.25B$ 34.44B$ 20.28B
Net Income From Continuing And Discontinued Operation
$ 5.12B$ 4.86B$ 11.84B$ 11.54B$ 4.62B$ 7.88B
Normalized Income
$ 10.40B$ 9.17B--$ 2.17B$ 9.75B
Interest Expense
------
EBIT
$ 9.87B$ 8.47B$ 15.71B$ 15.41B$ 5.85B$ 10.21B
EBITDA
$ 18.20B$ 17.17B$ 24.17B$ 23.93B$ 12.32B$ 12.27B
Currency in USD

AbbVie Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis